Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.81 |
| ▸ | ITK | Q08881 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.55 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349799 | 1.00 | EHMT2 (1.00) | EHMT2EHMT1ITKKDM4EMEN1 | |
| SCHEMBL25302284 | 0.90 | EHMT2 (1.00) | EHMT2EHMT1ITKKDM4EMEN1 | |
| SCHEMBL17915519 | 0.87 | EHMT2 (0.83) | EHMT2EHMT1ITKKDM4EMEN1 | |
| SCHEMBL16463988 | 0.87 | EHMT2 (0.77) | EHMT2EHMT1ITKKDM4E | |
| SCHEMBL21437365 | 0.83 | EHMT2 (0.71) | EHMT2EHMT1ITKKDM4EADORA2A | |
| SCHEMBL8225590 | 0.80 | EHMT2 (0.66) | EHMT2EHMT1ITKADORA2AOPRK1 | |
| SCHEMBL1467481 | 0.78 | ADORA2A (0.80) | EHMT2ITKADORA2A | |
| SCHEMBL5318309 | 0.77 | HDAC6 (0.76) | EHMT2EHMT1KDM4ETP53 | |
| SCHEMBL24845522 | 0.76 | OPRK1 (0.71) | EHMT2ITKKDM4EMEN1TSHR | |
| SCHEMBL24845486 | 0.76 | OPRK1 (0.71) | EHMT2ITKKDM4EMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254455-A1 | TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) - LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) FUSION PROTEINS | THE GENERAL HOSPITAL CORPORATION | 2024-08-01 | — | — | US | disclosed |
| US-11891631-B2 | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (LSD1) fusion proteins | THE GENERAL HOSPITAL CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| EP-3789405-A1 | TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) - LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) FUSION PROTEINS | The General Hospital Corporation (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3483185-B1 | TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) - LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) FUSION PROTEINS | MASSACHUSETTS GEN HOSPITAL (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3483185-A1 | TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) - LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) FUSION PROTEINS | The General Hospital Corporation (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2906602-B1 | TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) - LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) FUSION PROTEINS | MASSACHUSETTS GEN HOSPITAL (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2018190713-A1 | INHIBITORS OF LYSINE METHYLTRANSFERASE FOR TREATMENT OF PAIN | UMC UTRECHT HOLDING B.V. (NL) | 2018-10-18 | — | — | WO | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160201063-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160201063-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | disclosed |
| US-20150267176-A1 | TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) - LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) FUSION PROTEINS | NATIONAL INSTITUTES OF HEALTH | 2015-09-24 | — | — | US | disclosed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150267176-A1 | TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) - LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) FUSION PROTEINS | ZFX, ZNF277, ZFR | EHMT2 34/4885EHMT1 31/4885ITK 3709/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | EHMT2 250/4885EHMT1 495/4885ITK 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.